UC Davis Health Clinical Studies

A Study of Experimental Medicine Atezolizumab for Non-Small Cell Lung Cancer

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test the safety and effectiveness of experimental treatment with atezolizumab. It will be compared to a placebo (inactive treatment). Participants will be randomly assigned to one of the two treatment groups: -Experimental atezolizumab -Placebo Neither the study doctor nor the participants will know which treatment they receive. Both treatment groups will be combined with platinum-based chemotherapy. The study will involve participants with non-small cell lung cancer (NSCLC). The second part of the study will be "open-label." Participants will know which treatment they are receiving in the second part of the study.

Drug study, Phase 3
Any, age 18 years or older

A Study of the Safety of Experimental CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis (decreased lung function)

The purpose of this study is to test an experimental drug called CC-90001 in patients with Idiopathic pulmonary fibrosis (IPF).

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease of unknown cause. IPF leads to the stiffening and scarring of the lung tissue, which prevents the lungs from working properly. This includes limiting their ability to take in oxygen. This in turn results in debilitating symptoms including shortness of breath and a decreased ability to exercise. The purpose of this study is to test an experimental drug called CC-90001. “Experimental” means that the study drug is currently being tested. It is not approved for sale in the United States by the Food and Drug Administration (FDA). This study will test CC-90001 compared to placebo. A placebo is an inactive substance that contains no medicine. This study is being conducted to test the effect of CC-90001 on improving your IPF, and to see how well your body tolerates CC-90001. CC-90001 works by interfering with JNK (c-Jun N-terminal kinase), a protein that the body produces in various situations. Scientists have seen evidence that JNK participates in inflammation and scarring in some body tissues. This includes the lungs of patients with IPF. Thus we hope that by reducing the action of JNK, CC-90001 may help treat IPF by decreasing inflammation and fibrosis in the lungs. This study also includes testing of blood samples for biomarkers. Biomarkers are substances such as proteins in the blood that tell us how the drug is working in your body. The biomarker testing is mandatory. That means that you cannot participate in the study if you do not agree to participate in the biomarker testing. Further information on the biomarker testing can be found at the end of this document.

Drug study, Phase 2
Any, age 40 years or older

Study of Experimental Medicine (Poziotinib) in Patients With Non Small Cell Lung Cancer

Experimental medicine poziotinib may "target" mutations and stop the growth of this type of cancer

This study is for an investigational study drug called poziotinib. It will be used for the treatment of Non-Small Cell Lung Cancer where certain DNA mutations (EGFR or HER2 Exon 20 Insertion Mutations) are present. Poziotinib is a new type of treatment and is considered investigational. “Investigational” means that it has not yet been approved by the U.S. Food and Drug Administration (FDA). The surface of lung cells contain some proteins called the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). These proteins play an important part in cell growth and survival. When the proteins of these cells genetically change or have gene mutations, these and other changes can cause cancer or control the growth of cancer. Once these mutations have been identified, it is believed that this study’s treatment with poziotinib may "target" these mutations and stop the growth of this certain type of cancer. Poziotinib, the “study drug”, is one of a new group of treatments called “targeted therapies”. Targeted therapies are designed to slow or stop certain types cancer cells. They target specific changed or mutated molecules that help cancer cells grow or spread. Poziotinib is given by mouth in the form of a pill. Poziotinib has been studied in over 200 patients with advanced cancers to date.

Drug study, Phase 2
Any, age 18 years or older

A Study of Experimental INS1007 For Non-Cystic Fibrosis Bronchiectasis (damage to airways, making it difficult to clear mucus)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This is a clinical research study of an experimental drug called INS1007. “Experimental” means that the study drug is currently being tested in clinical research studies. We might not have all the information about it. INS1007 is not approved to treat non Cystic Fibrosis (CF) bronchiectasis by the Food and Drug Administration (FDA). It is undergoing clinical investigations to determine if INS1007 is safe and effective. INS1007 is taken as tablets and has been studied in animals and humans. Patients like you, with non CF bronchiectasis, may have problems with managing sputum movemen. You may also have worsening respiratory symptoms. INS1007 may help manage these issues. The purpose of this clinical research study is to evaluate the safety and effectiveness of INS1007 as a treatment for non-CF bronchiectasis. We also want to measure the concentration of INS1007 in the blood after treatment.

Drug study, Phase 2
Any, age 18 to 85 years old

Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome

The study team wants to know if adding a sigh-type of breath to a ventilator reduces chances of developing more serious lung problems.

When patients have breathing problems, some may need support from a machine that helps them breathe. This machine is called a mechanical ventilator. Most of the time the machine works by delivering the same amount of air each time the patient takes, or is given, a breath. This study plans to examine adding large breaths, like you take when you sigh or yawn. These will be given at a rate that is like the rate people normally sigh. The study team wants to know if adding this type of breath will reduce the chance of you developing more serious lung problems.

Other study
Any, age 18 to 89 years old
Loading